The significance of tumor microenvironment for immunotherapy in melanoma and non-melanoma skin cancer
Immune checkpoint inhibitors (ICIs), such as anti-PD-1 antibody, have significantly changed the treatment landscape not only for unresectable melanoma but also for non-melanoma skin cancers. In addition, anti-PD-1 antibody administration methods have evolved and are now used in both the neoadjuvant...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-08-01
|
| Series: | Immunological Medicine |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/25785826.2025.2550795 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849224398875131904 |
|---|---|
| author | Taku Fujimura |
| author_facet | Taku Fujimura |
| author_sort | Taku Fujimura |
| collection | DOAJ |
| description | Immune checkpoint inhibitors (ICIs), such as anti-PD-1 antibody, have significantly changed the treatment landscape not only for unresectable melanoma but also for non-melanoma skin cancers. In addition, anti-PD-1 antibody administration methods have evolved and are now used in both the neoadjuvant and adjuvant settings. As these treatment strategies have been evaluated, it has become clear that understanding the role of the tumor microenvironment (TME) is critical to the success of anti-PD-1 antibody-based immunotherapy. For example, racial differences in the efficacy of immunotherapy in melanoma are influenced not only by tumor-related factors such as tumor mutational burden and microsatellite instability, but also by components of the TME, including tumor-associated macrophages, cancer-associated fibroblasts, and tumor-infiltrating lymphocytes (TILs), all of which can affect the therapeutic outcome of ICIs. Furthermore, studies conducted during the development of neoadjuvant therapies have shown that tumor-reactive TILs are densely localized within primary tumors and are closely associated with both treatment efficacy and the occurrence of immune-related adverse events. In this review, we discuss the therapeutic efficacy of currently available anti-PD-1 antibody-based immunotherapies for skin cancer and examine the role of the TME in influencing these therapeutic outcomes. |
| format | Article |
| id | doaj-art-dae7366db8cd4a53a8b59c07b66d1f07 |
| institution | Kabale University |
| issn | 2578-5826 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Immunological Medicine |
| spelling | doaj-art-dae7366db8cd4a53a8b59c07b66d1f072025-08-25T11:03:11ZengTaylor & Francis GroupImmunological Medicine2578-58262025-08-0111110.1080/25785826.2025.2550795The significance of tumor microenvironment for immunotherapy in melanoma and non-melanoma skin cancerTaku Fujimura0Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, JapanImmune checkpoint inhibitors (ICIs), such as anti-PD-1 antibody, have significantly changed the treatment landscape not only for unresectable melanoma but also for non-melanoma skin cancers. In addition, anti-PD-1 antibody administration methods have evolved and are now used in both the neoadjuvant and adjuvant settings. As these treatment strategies have been evaluated, it has become clear that understanding the role of the tumor microenvironment (TME) is critical to the success of anti-PD-1 antibody-based immunotherapy. For example, racial differences in the efficacy of immunotherapy in melanoma are influenced not only by tumor-related factors such as tumor mutational burden and microsatellite instability, but also by components of the TME, including tumor-associated macrophages, cancer-associated fibroblasts, and tumor-infiltrating lymphocytes (TILs), all of which can affect the therapeutic outcome of ICIs. Furthermore, studies conducted during the development of neoadjuvant therapies have shown that tumor-reactive TILs are densely localized within primary tumors and are closely associated with both treatment efficacy and the occurrence of immune-related adverse events. In this review, we discuss the therapeutic efficacy of currently available anti-PD-1 antibody-based immunotherapies for skin cancer and examine the role of the TME in influencing these therapeutic outcomes.https://www.tandfonline.com/doi/10.1080/25785826.2025.2550795Immune checkpoint inhibitorsanti-PD-1 antibodycombination therapytolerancetumor microenvironment |
| spellingShingle | Taku Fujimura The significance of tumor microenvironment for immunotherapy in melanoma and non-melanoma skin cancer Immunological Medicine Immune checkpoint inhibitors anti-PD-1 antibody combination therapy tolerance tumor microenvironment |
| title | The significance of tumor microenvironment for immunotherapy in melanoma and non-melanoma skin cancer |
| title_full | The significance of tumor microenvironment for immunotherapy in melanoma and non-melanoma skin cancer |
| title_fullStr | The significance of tumor microenvironment for immunotherapy in melanoma and non-melanoma skin cancer |
| title_full_unstemmed | The significance of tumor microenvironment for immunotherapy in melanoma and non-melanoma skin cancer |
| title_short | The significance of tumor microenvironment for immunotherapy in melanoma and non-melanoma skin cancer |
| title_sort | significance of tumor microenvironment for immunotherapy in melanoma and non melanoma skin cancer |
| topic | Immune checkpoint inhibitors anti-PD-1 antibody combination therapy tolerance tumor microenvironment |
| url | https://www.tandfonline.com/doi/10.1080/25785826.2025.2550795 |
| work_keys_str_mv | AT takufujimura thesignificanceoftumormicroenvironmentforimmunotherapyinmelanomaandnonmelanomaskincancer AT takufujimura significanceoftumormicroenvironmentforimmunotherapyinmelanomaandnonmelanomaskincancer |